Lupin, Inc.

Medicis Pharmaceutical Corporation

Ashish Ashokrao Deshmukh

Sajeev Chandran

Shirishkumar Kulkarni

Pravin Meghrajji Bhutada

Mitchell S Wortzman

Douglas Anthony Bakan

Satish Kumar Dalal

Chirag Anilkumar Shah

Dhananjay Sadashiv Bakhle

Snehal Ameet Gadve

Neha Sharma

Douglas Bakan

Mitchell Wortzman

The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.

Controlled release pharmaceutical dosage forms

A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37&#xb0; C., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.

Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters

A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tof tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.

Controlled release pharmaceutical compositions of tapentadol

The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.

Oral controlled release pharmaceutical compositions of Bepotastine

Oral controlled release pharmaceutical compositions of bepotastine

Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry comprising a carbonic anhydrase inhibitor and a surfactant; b) preparing a polymer slurry comprising a polymer and water; c) preparing a solution comprising tonicity and preservative agents; d) mixing the polymer slurry of step b and the solution of step c, to form a vehicle concentrate and adjusting pH; e) adding the slurry of step a, to the vehicle concentrate of step d and mixing to homogenize; f) autoclaving the mixture of step e; g) sizing the mixture of step f, under aseptic condition.

Process for preparing pharmaceutical ophthalmic compositions

Growing community of inventors

Pune, India

Ashish Ashokrao Deshmukh